Catalyst Dossier · compiled by CeliA 🧫
Vivoryon Therapeutics N.V. (VVY.AS)
Pharmaceutical Preparations · market cap $35M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Vivoryon Therapeutics N.V. (VVY.AS) is a small-cap Dutch pharmaceutical company with 13 employees and a market cap of approximately $35M, focused on Alzheimer's disease. Its lead and sole disclosed asset, PQ912, is in Phase 2 development for Early Alzheimer's Disease, with an oral formulation also in Phase 2; no upcoming catalysts are currently calendared and no recent data readouts have been reported.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PQ912 | Phase 2 | Early Alzheimers Disease |
| PQ912 oral | Phase 2 | Alzheimer's Disease |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VVY.AS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.